| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.0025 | 1 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0025 | 1 |